Status:
COMPLETED
AFP Model and Liver Transplantation.
Lead Sponsor:
Austral University, Argentina
Conditions:
Liver Carcinoma
Liver Transplant Disorder
Brief Summary
Background \& Aim: Presence of microvascular invasion (mvi) in the explanted liver defines a higher risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). The aim of th...
Detailed Description
Introduction Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a catastrophic event, with limited therapeutics and poor survival \[1\]. Prior to 1990s, transplantation f...
Eligibility Criteria
Inclusion
- . Criteria for inclusion required patients to be adult cirrhotic or non-cirrhotic recipients with confirmed HCC in the explanted liver.
Exclusion
- other tumors than HCC are confirmed in the explanted liver,
- there are missing relevant information;
- extrahepatic or macrovascular tumor invasion were observed during pre transplant evaluation or in the explanted liver
- incidental HCC,
- had a previous liver transplant
Key Trial Info
Start Date :
November 11 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 12 2018
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT03775863
Start Date
November 11 2017
End Date
December 12 2018
Last Update
December 19 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad Austral
Pilar, Buenos Aires, Argentina, 1629
2
Henri Mondor Hospital, University of Paris-Est.
Créteil, Paris, France